7OPP

Crystal structure of the Rab27a fusion with Slp2a-RBDa1 effector for SF4 pocket drug targeting


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.32 Å
  • R-Value Free: 0.201 
  • R-Value Work: 0.162 
  • R-Value Observed: 0.163 

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.1 of the entry. See complete history


Literature

Identification of the first structurally validated covalent ligands of the small GTPase RAB27A.

Jamshidiha, M.Lanyon-Hogg, T.Sutherell, C.L.Craven, G.B.Tersa, M.De Vita, E.Brustur, D.Perez-Dorado, I.Hassan, S.Petracca, R.Morgan, R.M.Sanz-Hernandez, M.Norman, J.C.Armstrong, A.Mann, D.J.Cota, E.Tate, E.W.

(2022) RSC Med Chem 13: 150-155

  • DOI: https://doi.org/10.1039/d1md00225b
  • Primary Citation of Related Structures:  
    7OPP, 7OPQ, 7OPR

  • PubMed Abstract: 

    Rab27A is a small GTPase, which mediates transport and docking of secretory vesicles at the plasma membrane via protein-protein interactions (PPIs) with effector proteins. Rab27A promotes the growth and invasion of multiple cancer types such as breast, lung and pancreatic, by enhancing secretion of chemokines, metalloproteases and exosomes. The significant role of Rab27A in multiple cancer types and the minor role in adults suggest that Rab27A may be a suitable target to disrupt cancer metastasis. Similar to many GTPases, the flat topology of the Rab27A-effector PPI interface and the high affinity for GTP make it a challenging target for inhibition by small molecules. Reported co-crystal structures show that several effectors of Rab27A interact with the Rab27A SF4 pocket ('WF-binding pocket') via a conserved tryptophan-phenylalanine (WF) dipeptide motif. To obtain structural insight into the ligandability of this pocket, a novel construct was designed fusing Rab27A to part of an effector protein (fRab27A), allowing crystallisation of Rab27A in high throughput. The paradigm of KRas covalent inhibitor development highlights the challenge presented by GTPase proteins as targets. However, taking advantage of two cysteine residues, C123 and C188, that flank the WF pocket and are unique to Rab27A and Rab27B among the >60 Rab family proteins, we used the quantitative Irreversible Tethering (qIT) assay to identify the first covalent ligands for native Rab27A. The binding modes of two hits were elucidated by co-crystallisation with fRab27A, exemplifying a platform for identifying suitable lead fragments for future development of competitive inhibitors of the Rab27A-effector interaction interface, corroborating the use of covalent libraries to tackle challenging targets.


  • Organizational Affiliation

    Department of Life Sciences, Imperial College London London SW7 2AZ UK e.cota@imperial.ac.uk.


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Synaptotagmin-like protein 2,Ras-related protein Rab-27AA,
B [auth C]
230Homo sapiensMutation(s): 3 
Gene Names: SYTL2KIAA1597SGA72MSLP2SLP2ARAB27ARAB27
EC: 3.6.5.2
UniProt & NIH Common Fund Data Resources
Find proteins for P51159 (Homo sapiens)
Explore P51159 
Go to UniProtKB:  P51159
PHAROS:  P51159
GTEx:  ENSG00000069974 
Find proteins for Q9HCH5 (Homo sapiens)
Explore Q9HCH5 
Go to UniProtKB:  Q9HCH5
PHAROS:  Q9HCH5
GTEx:  ENSG00000137501 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupsP51159Q9HCH5
Sequence Annotations
Expand
  • Reference Sequence
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.32 Å
  • R-Value Free: 0.201 
  • R-Value Work: 0.162 
  • R-Value Observed: 0.163 
  • Space Group: P 31 2 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 117.71α = 90
b = 117.71β = 90
c = 115.67γ = 120
Software Package:
Software NamePurpose
PHENIXrefinement
PHENIXrefinement
PHASERphasing
DIALSdata scaling
DIALSdata reduction

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Cancer Research UKUnited KingdomC29637/A20781

Revision History  (Full details and data files)

  • Version 1.0: 2022-04-06
    Type: Initial release
  • Version 1.1: 2024-01-31
    Changes: Data collection, Refinement description